ESMO Endorses HLB's CAM-RIVO for First-Line Liver Cancer Treatment Ahead of FDA Decision
核心洞察
HLB (搜索)'s combination therapy CAM-RIVO has been added to ESMO (搜索) guidelines as a first-line treatment for hepatocellular carcinoma (搜索), receiving a "very strong" clinical evidence rating.
The drug combination demonstrates unprecedented efficacy with a median overall survival of 23.8 months, marking the longest survival data recorded for liver cancer (搜索) therapy.
The ESMO (搜索) endorsement comes at a crucial time, with an FDA decision expected by March 20, following the drug's previous approval in China.
HLB (搜索) has secured a significant endorsement from the European Society for Medical Oncology (ESMO (搜索)) for its liver cancer (搜索) combination therapy CAM-RIVO, comprising rivoceranib and camrelizumab, just weeks before a critical FDA decision deadline.
The ESMO (搜索) guidelines, updated for the first time since 2022, have recognized CAM-RIVO as a first-line treatment for hepatocellular carcinoma (搜索) (HCC), backed by Level I evidence - the highest clinical evidence rating. This unusual pre-approval endorsement highlights the therapy's promising potential in the treatment landscape.
Unprecedented Survival Data
CAM-RIVO has demonstrated remarkable efficacy, achieving a median overall survival (mOS) of 23.8 months - the longest survival data reported for any liver cancer (搜索) therapy to date. The treatment combines rivoceranib, an anti-angiogenic VEGFR-TKI (搜索), with camrelizumab, a PD-1 (搜索) checkpoint inhibitor, offering a novel approach to targeting liver cancer.
Competitive Advantages in Treatment Landscape
Unlike existing front-line therapies such as bevacizumab plus atezolizumab or durvalumab plus tremelimumab combinations, CAM-RIVO doesn't require pre-screening for gastrointestinal bleeding risks. This advantage could make it a preferred choice for physicians seeking effective but less burdensome treatment options.
Regulatory Journey and Market Impact
HLB (搜索), in partnership with Jiangsu Hengrui Pharmaceuticals (搜索), submitted a new drug application for CAM-RIVO as a first-line liver cancer (搜索) treatment in 2023. While the FDA initially issued a complete response letter requesting additional data, the therapy is now under priority review with a decision expected by March 20.
The treatment has already received approval in China, and the recent ESMO (搜索) endorsement has significantly boosted market confidence. HLB (搜索)'s stock responded positively, surging nearly 10% following the announcement, with affiliated companies also experiencing substantial gains.
Clinical Significance
The endorsement carries particular weight given the global burden of liver cancer (搜索), which ranks as the sixth most common cancer worldwide with over 900,000 new cases annually. HCC, representing 80% of liver cancer cases, shows increasing prevalence in Europe and North America, underscoring the urgent need for effective first-line treatments.
"This strong recommendation from ESMO (搜索) signals that CAM-RIVO is already being recognized as an international standard for liver cancer (搜索) treatment," stated Han Yong-hae, CEO of HLB (搜索) Life Science and CTO of HLB Group. "It's an encouraging sign for upcoming regulatory decisions in both the U.S. and Europe."